+ Watch IMGN
on My Watchlist
The Company develops antibody-based anticancer therapeutics.
see a lot of value here, said Cramer. At current levels I'm a buyer
High valuations and low relative strength. Will probably continue to slide.
Big pipeline of potentially profitable new drugs.
I am hoping for a big year with clinical trials and partnered products.
I ended my underperform on ImmunoGen a little prematurely in order to align my CAPS picks with the zzporte portfolio, so I missed my long-awaited catharsis of the sudden discontinuation of the NORTH trial for futility. Nevertheless, the failure did provide me a better entry for this green thumb that supports our real life position of 650 shares at a cost basis of 16. Kadcyla royalties remain mostly theoretical but European approval of Kadcyla, positive results of TH3RESA, and upcoming data from the MARIANNE trial of Kadcyla as first line treatment in HER-2 positive breast cancer should help Immunogen with the investors that like to bank on potnetial.
1yr sales grwth 117% ,3yr sales grwth 33%
In the sweet spot of cancer treatment, endorsed by big pharma
UBS must be trying to drive this down, don't fall for it...
With its AntiSense technology, this is a Biotech winner LT!
The technology is bearing fruit and could be applied to multiple cancers.
Immunogen's proprietary TAP technology is licensedto Genentech for their groundbreaking drug for HER2-positive metastatic breast cancer. This drug looks all set for approval within the very near future and its clinical trials data show significant increases in overall survival. This is a treatment that has the potential to transform the eway we treat breast cancer and has implications for other tumor types, too. When the drug is approved, the money will start to roll in for Immunogen.
Value at this price.
Undervalued comparing with SGEN
just watching it go down. Will buy around 8$
It only take 1 good drug
This is a great company based on a solid science foundation. It's platform is proving to work. Not only did TDM1 have phenomenal phase 2 results, but its partnerships with other companies are also doing very well. This indicates a lot more future value when these products get through development. I see this as a buy and anticipate the company will be acquired someday...hopefully by Roche.
Good approach to cancer therapy. A step away from traditional chemotherapy. Any breakthrough in adenocarcinoma tumor therapy will lead to application for prostate carcinoma. We have not had any real therapeutic breakthrough in a long time. The tools are now in the workshop!
Phase 2 clinical trials of cancer drug were characterized as striking, CEO claims Phase three trials may be done by 2014. I just like all the news so I will take a flyer...
BATS data provided in real-time. NYSE, NASDAQ and NYSEMKT data delayed 15 minutes.
Real-Time prices provided by BATS. Market data provided by Interactive Data.
Company fundamental data provided by Morningstar. Earnings Estimates, Analyst Ratings and Key Statistics provided by Zacks.
SEC Filings and Insider Transactions provided by Edgar Online.
Powered and implemented by Interactive Data Managed Solutions. Terms & Conditions